EMEA, Health Canada link up
This article was originally published in The Tan Sheet
Executive Summary
The health authorities will share legislation under development, draft guidance documents and non-public safety and efficacy data on regulated products, according to an implementation plan for regulatory cooperation published April 2. The European Medicines Agency and Health Canada also call for routine communication about good manufacturing practice inspections performed outside the respective territories and will allow access to each other's GMP database information. The cooperation plan says the partnership will seek to include U.S. FDA in joint activities "to minimize duplication of effort." EMEA, FDA and Australia's Therapeutic Goods Administration have launched a pilot to share GMP inspection information (1"The Tan Sheet" Jan. 19, 2009, p. 9)
You may also be interested in...
Pilot Takes Off For Inspecting API Manufacturers By U.S., Europe, Australia
FDA and its counterparts in the European Union and Australia have divided responsibilities for inspecting specific active pharmaceutical ingredient facilities in third-country locations in the next 18 months as part of a pilot to monitor more sites
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.